The cytosolic Ca 2ϩ /Mg 2ϩ -binding protein ␣-parvalbumin (␣-Parv) has been shown to accelerate cardiac relaxation; however, beyond an optimal concentration range, ␣-Parv can also diminish contractility. Mathematical modeling suggests that increasing Parv's Mg 2ϩ affinity may lower the effective concentration of Parv ([Parv]) to speed relaxation and, thus, limit Parv-mediated depressed contraction. Naturally occurring ␣/␤-Parv isoforms show divergence in amino acid primary structure (57% homology) and cation-binding affinities, with ␤-Parv having an estimated 16% greater Mg 2ϩ affinity and ϳ200% greater Ca 2ϩ affinity than ␣-Parv. We tested the hypothesis that, at the same or lower estimated [Parv], mechanical relaxation rate would be more significantly accelerated by ␤-Parv than by ␣-Parv. Dahl salt-sensitive (DS) rats were used as an experimental model of diastolic dysfunction. Relaxation properties were significantly slowed in adult cardiac myocytes isolated from DS rats compared with controls: time from peak contraction to 50% relaxation was 57 Ϯ 2 vs. 49 Ϯ 2 (SE) ms (P Ͻ 0.05), validating this model system. DS cardiac myocytes were subsequently transduced with ␣-or ␤-Parv adenoviral vectors. Upon Parv gene transfer, ␤-Parv caused significantly faster relaxation than ␣-Parv (P Ͻ 0.05), even though estimated [␤-Parv] was ϳ10% of [␣-Parv]. This comparative analysis showing distinct functional outcomes raises the prospect of utilizing naturally occurring Parv variants to address disease-associated slowed cardiac relaxation. gene transfer; mechanical relaxation CONGESTIVE HEART FAILURE (CHF) is an increasingly frequent cause of cardiovascular morbidity and mortality (3, 4, 18) . Heart failure occurs as a result of systolic and/or diastolic dysfunction. In humans, it is estimated that 40% of CHF involves diastolic dysfunction in the absence of systolic dysfunction (21). Although structural changes partly account for decreased myocardial compliance during diastole, diastolic dysfunction is also evident at the level of the cardiac myocyte. Human and animal studies show that slowed myocyte relaxation is coupled to prolonged Ca 2ϩ transients, delayed Ca 2ϩ sequestration, and elevations in diastolic Ca 2ϩ levels (1, 10, 16, 24, 26, 28) . Myocardial cytoplasmic Ca 2ϩ removal is mediated by sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA2a), phospholamban, and the Na ϩ /Ca 2ϩ exchanger. These proteins are involved with the translocation of Ca 2ϩ from the cytoplasm to the sarcoplasmic reticulum (SERCA and phospholamban) and/or extruded from the cell (Na ϩ /Ca 2ϩ exchanger) to promote relaxation and maintain cytosolic Ca 2ϩ homeostasis (13, 22) . A common feature of heart failure is alteration in the expression of Ca 2ϩ -handling proteins, including a decrease in SERCA2a expression (1, 13, 20, 26, 27) . Despite numerous studies focusing on the molecular mechanism of diastolic dysfunction and heart failure, clinically relevant therapeutic strategies to redress diastolic dysfunction by improving Ca 2ϩ -handling mechanisms have yet to be developed.
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A recent approach to redress diastolic dysfunction has focused on the introduction of a non-energy-dependent mechanism for accelerating relaxation. Specifically, ␣-parvalbumin (␣-Parv), a small (11-kDa) Ca 2ϩ -binding protein not typically expressed in mammalian cardiac myocytes, has been demonstrated to accelerate relaxation in a variety of models of diastolic dysfunction (5-9, 17, 25, 29) . The proposed mechanism for ␣-Parv-based acceleration of cardiac relaxation is described in detail elsewhere (6, 7, 9) . Briefly, ␣-Parv functions as a delayed Ca 2ϩ buffer, where systolic Ca 2ϩ binding is limited by the slow off-rate of Mg 2ϩ from ␣-Parv that must occur before Ca 2ϩ binding. Ideally, this would exclusively occur in early to mid diastole to speed relaxation while preserving contraction amplitude (6) . Whereas ␣-Parv has been shown to correct diastolic dysfunction in disease models and aging (5, 17, 25) , ␣-Parv expression-dependent depressed cellular contraction is evident. In vitro studies have defined an optimal ␣-Parv expression window of ϳ10 -100 M to cause myocyte relaxation without compromising systolic function. Mathematical modeling predicts that modification of ␣-Parv's metal-binding affinities could be useful in enhancing the functional properties of ␣-Parv in cardiac myocytes (7, 9) . Previous studies exclusively used ␣-Parv to redress cardiac diastolic dysfunction (5) (6) (7) (8) (9) . In nature, two distinct Parv isoforms, ␣-and ␤-Parv, have ϳ43% dissimilarity in amino acid sequence (Supplemental Fig. 1 ; supplemental data for this article are available at the American Journal of Physiology-Heart and Circulatory Physiology website). Thus it is postulated that the divergence in Parv isoform primary structure, including select amino acid differences in the more conserved E-F hand consensus sequence, could translate to alterations in cation binding in the intact cardiac myocyte. Biochemical assessment of isolated Parv isoforms in solution provides evidence that ␤-Parv binds Mg 2ϩ and Ca 2ϩ more tightly than ␣-Parv (12; unpublished observations). An increase in Mg 2ϩ affinity, through decreased off-rate, in particular, is modeled to further delay the Ca 2ϩ -buffering function of Parv. In this study, we compared for the first time the direct effects of ␣-and ␤-Parv on myocyte performance to test the hypothesis that ␤-Parv would cause faster relaxation than ␣-Parv in cardiac myocytes. Sarcomere shortening and relaxation properties on isolated adult cardiac myocytes were obtained from a hypertensive rat model of diastolic dysfunction and CHF (11) . The overall objective was to gain insight into the functional relationship between Parv isoforms and shortening and relaxation kinetics in a model of diastolic dysfunction. To optimize analysis and interpretation, we focused on isolated single cardiac myocytes and used an experimental approach of in vitro gene transfer of ␣-or ␤-Parv. Adult rat cardiac myocytes obtained from Dahl salt-sensitive (DS) rats were fed a high-salt diet to yield a diastolic dysfunction phenotype (11) . The DS rat has a renin gene polymorphism and a mutation in the ␣ 1 -Na ϩ -K ϩ -ATPase gene, such that a high-salt diet results in hypertension, with low levels of renin and aldosterone. Recently, Doi and colleagues (11) demonstrated a significantly different progression in hypertension between DS rats fed a high-salt (HS) diet starting at 7 wk of age and those starting the diet at 8 wk of age. Specifically, DS rats fed a high-salt diet starting at 7 wk of age developed hypertension and overt signs of CHF due to diastolic dysfunction with preserved systolic performance.
Our findings of significantly slowed relaxation with preserved shortening amplitude in cardiac myocytes from HS animals validate this as a useful cellular model of diastolic dysfunction with preserved systolic performance. Gene transfer of Parv isoforms demonstrated correction of slowed relaxation, with ␤-Parv causing significantly faster relaxation than ␣-Parv (P Ͻ 0.05). These results are the first to indicate that naturally occurring variations in Parv primary structure can be useful in tailoring specific contractile performance outcomes in cardiac myocytes with diastolic dysfunction. Experimental time line for high-salt (HS) diet induction and in vivo hemodynamic characterization of hypertension, hypertrophy, and diastolic dysfunction in the Dahl salt-sensitive (DS) rat (A) using tail-cuff manometry to record systolic blood pressure during weeks 7, 9, 11, 13, 15, and 17 (B) and echocardiography recorded during weeks 6, 8, 10, 12, 14, 16 , and 18 to determine left ventricular (LV) mass (C), relative wall thickness (D), LV mass-tobody weight ratio (E), ejection fraction (F), and lateral annular ratio of early to late filling waves (E-to-A ratio, G). DS rats were fed standard (0.04% NaCl) rodent chow [low-salt (control), n ϭ 8] or purified rodent chow containing 8.0% NaCl (high salt, n ϭ 8 Sixteen 4-to 5-wk-old male DS rats (Brookhaven variety) were obtained from Harlan (Indianapolis, IN). All rats were fed standard rat chow (0.4% NaCl) ad libitum during a 1-wk travel-recovery period. Subsequently, rats were randomly assigned to a control group (n ϭ 8), which was continuously fed a standard rodent chow, or a high-salt (HS) group (n ϭ 8), which was switched to a diet consisting of commercially available purified rodent chow (Dyets) containing 8% NaCl beginning at 7 wk of age, following published protocols (11) .
Systolic blood pressure was measured at alternating weeks with a tail-cuff system (IITC, Woodland Hills, CA) starting at 7 wk of age to document the progression of hypertension.
Echocardiography. Rats were continuously anesthetized with 1.5% inhaled isoflurane-in-oxygen while echocardiograms were performed using a GE Vivid 7 and an S10-MHz phased-array transducer. Systolic and diastolic dimensions and wall thickness were measured in M-mode in the parasternal short-axis view at the level of the 
Values are means Ϯ SE. Dahl salt-sensitive (DS) rats were fed normal (0.4% NaCl) rodent chow (control) or purified (8.0% NaCl) rodent chow (HS). LVET, left ventricular (LV) ejection time; MVctetrt, time for mitral valve closure ϩ ejection ϩ relaxation. *P Ͻ 0.05 vs. control in the same week. †P Ͻ 0.05 vs. previous week within group. Values are means Ϯ SE. E and A, peak early and late diastolic velocity; E/A, ratio of peak early to late diastolic filling; Vcfc, velocity of circumferential shortening corrected for heart rate. *P Ͻ 0.05 vs. control in the same week. papillary muscles. Fractional shortening and ejection fraction were calculated from the M-mode parasternal short-axis view. Diastolic function was assessed by conventional pulsed-wave spectral Doppler analysis of mitral valve inflow patterns [early (E) and late (A) filling waves]. Doppler tissue imaging (DTI) was used to measure the early (Ea) and late (Aa) diastolic tissue velocities of the mitral annulus, the septal annulus, and the posterior wall.
Adult cardiac myocyte isolation, gene transfer, and primary culture. Isolated adult (18-to 20-wk-old) cardiac myocytes were obtained from control and HS-treated DS rats. Cardiac myocyte isolation and gene transfer were performed as previously described (7, 30) . Briefly, cardiac myocytes were plated and incubated for 2 h with no virus (control), ␣-Parv (500 multiplicity of infection), or ␤-Parv (200 multiplicity of infection). These doses permit functional testing 3 days after gene transfer with 95-100% gene transfer efficiency. At ϳ18 h after isolation and gene transfer, myocytes used for functional studies were transferred to stimulating chambers containing M199ϩ solution (Sigma) supplemented with 10 mM glutathione, 26.2 mM sodium bicarbonate, 0.02% bovine serum albumin, and 50 U/ml penicillinstreptomycin, with pH adjusted to 7.4 (7). Myocytes were maintained under field stimulation (0.2 Hz, 7.0 V) using a MyoPacer field stimulator (Ionoptix, Milton, MA). Acutely isolated myocyte width/ length dimensions were measured directly via light microscopy.
Recombinant adenoviruses. The ␣-Parv recombinant adenoviral vector was constructed as previously described (30) . The ␤-Parv recombinant adenovirus contained the carp ␤-Parv cDNA. Gene expression for each vector was under the control of the cytomegalovirus promoter, and the simian virus 40 provided the polyadenylation signal. High-titer, plaque-purified adenoviral stocks were produced and purified, and viral aliquots were stored at Ϫ80°C.
Western blot analysis. Myocytes were collected 3 days after isolation in 4ϫ Laemmli sample buffer, as previously described (7). Briefly, we obtained samples by applying 10 l of sample buffer to an individual coverslip (ϳ20,000 myocytes) and scraping with a pulled capillary pipette. Collected samples were stored in sample buffer at Ϫ20°C. For immunodetection, commercially available monoclonal antibodies were used according to the manufacturer's instructions with corresponding dilutions: 5c5 ␣-actin (1:1,000 dilution; catalog no. A2172, Sigma) and Parv 19 (1:1,000 dilution; catalog no. P3088, Sigma). For detection in both cases, goat anti-mouse antibody conjugated to horseradish peroxidase (1:10,000 dilution; catalog no. A9917, Sigma) was used as the secondary antibody. Detection was performed using the ECL Western blotting detection kit (Amersham Biosciences). Samples collected from rat superior vastus lateralis (SVL) muscle were used as a positive control for [Parv] . For all Parv samples, the level of Parv expression was normalized to the level of actin expression. The same normalization was also performed on the positive control (SVL). Finally, the Parv-to-actin ratio of Parv-transduced myocytes was normalized to the Parv-to-actin ratio of SVL samples to give the estimated Parv concentration in myocytes relative to the Parv level in SVL. The estimated Parv concentration in myocytes is based on a value of 0.4 mM, which was reported for [Parv] in rat SVL (14) .
Sarcomere shortening. All experiments were performed at 37 Ϯ 1°C in M199ϩ solution. Unloaded sarcomere shortening data were collected as previously described (8) . Briefly, sarcomere-shortening data were collected at 240 Hz using the contractility system of Ionoptix. A standardized search pattern was used to sample ϳ8 -10 myocytes responsive to electrical stimulation from each coverslip per treatment group. The myocyte transient analysis software (Ionoptix) was used to determine baseline (BL) sarcomere length, peak shortening, percent shortening [(peak height/BL)(100)], time to maximal peak shortening, and time from peak to 25, 50, and 75% relengthening, as well as shortening velocity (Ϫdl/dt, where l is sarcomere length) normalized to peak height and relaxation velocity (dl/dt) normalized to peak height. Statistical analysis. All statistical analyses were performed using SigmaStat software. For experiments where myocytes were studied as populations for each treatment, one-way ANOVA was used to determine any significant differences among groups. When significant differences were detected, pair-wise multiple comparisons (Tukey's test) were performed to determine interaction effects. For experiments determining the effects of the control vs. the HS diet in DS rats, unpaired t-tests were used to determine significance (P Ͻ 0.05). Values are means Ϯ SE.
RESULTS
Previous reports indicated that initiation of a high-salt diet in DS rats at 7 wk of age results in chronic hypertension, which progresses to a model of CHF primarily associated with diastolic dysfunction independent of marked systolic dysfunction by 19 wk of age (11) . This rodent model of diastolic dysfunction was selected specifically to determine whether this phenotype is present in isolated cardiac myocytes and to test the effectiveness of Parv isoforms to redress the diastolic dysfunction. The protocol for the study is outlined in Fig. 1 . The HS diet was initiated at 7 wk of age and maintained for 3 mo. On alternate weeks, tail-cuff blood pressures were measured and echocardiography was performed. In agreement with previous reports, systolic blood pressure in HS-treated animals increased steadily and significantly (Fig. 1) . By week 15, systolic pressure was Ͼ80 mmHg higher in HS-treated than in control animals. Heart rate, stroke volume, and cardiac index were not altered (Table 1) . Further echocardiographic assessment showed a progressive and significant increase in left ventricular (LV) relative wall thickness in HS-treated DS animals (Fig. 1) . LV mass and LV mass-to-body weight ratio were also significantly increased in these animals (Fig. 1) . DTI analysis showed that the lateral annular E-to-A ratio was significantly depressed in the HS group at weeks 14 -18 relative to controls (Fig. 1) . Because DTI lateral annular E-to-A ratio is a marker of diastolic performance, a decrease in this ratio provides strong evidence of organ-level diastolic dysfunction (Fig. 1) . The statistically significant differences in ejection fraction (%), fractional shortening, and velocity of circumferential shortening between HS and control animals are indicative of systolic dysfunction (Fig. 1, Tables 2, and 3) . Collectively, these Fig. 2 . Morphological characteristics of cardiac myocytes isolated from DS rats fed standard (0.04% NaCl) rodent chow (low salt, n ϭ 96) or purified rodent chow containing 8% NaCl (high salt, n ϭ 94). A: representative images of myocytes (ϫ20 magnification) obtained from low-and high-salt rats. Scale bar, 20 m. After 12 wk of a high-salt diet, myocyte length (B) and myocyte area (C) were significantly increased 20% and 44%, respectively. Values are means Ϯ SE. *P Ͻ 0.05 vs. low salt. Fig. 3 . In vitro sarcomere shortening characterization of cardiac myocytes isolated from DS rats fed standard (0.04% NaCl) rodent chow (low salt, n ϭ 14) or purified rodent chow containing 8% NaCl (high salt, n ϭ 68). A: representative normalized sarcomere shortening traces at day 3 in primary culture. B and C: summary of baseline sarcomere length (Baseline), peak shortening sarcomere length (Peak), and percent shortening, as well as time to peak shortening and time from peak to 75% relaxation. Values are means Ϯ SE. *P Ͻ 0.05 vs. low salt.
organ-level findings indicate diastolic and systolic dysfunction in this model system.
Cardiac myocytes isolated at week 19 showed marked differences in cellular morphology (Fig. 2) . Adult cardiac myocytes were significantly longer (Ͼ20%) and larger in area (Ͼ40%) in HS than in control animals. The increase in endto-end myocyte length was due to addition of more sarcomeres in series in the HS group, inasmuch as the average sarcomere length was not significantly different between groups (P Ͼ 0.05; Fig. 3 ). Acutely isolated single cardiac myocytes demonstrated alterations in mechanical performance in the HS group. Specifically, time to peak and time from peak shortening to 75% relaxation were significantly prolonged in HS vs. control animals (Fig. 3) . This is interpreted at the myocyte level as a delay in onset of relaxation and a slowing of relaxation performance in the HS group. Contractility was not significantly different between groups. Thus, at the singlemyocyte level, HS produced cellular diastolic dysfunction with preserved systolic function (contractility).
Cardiac myocytes isolated from HS animals were transduced with recombinant adenoviral vectors harboring ␣-or ␤-Parv expression cassettes. At 72 h after gene transfer, we assessed myocytes for contractile function by monitoring sarcomere length changes in response to electrical stimulation at 37°C (Fig. 4) . Basal sarcomere length was significantly increased to the same extent by ␣-and ␤-Parv in HS myocytes (Fig. 4B) . During contraction, there was a similar reduction in myocyte shortening (%) by ␣-and ␤-Parv (Fig. 4D ). These results with ␣-Parv are in agreement with previous studies of Parv gene transfer to normal cardiac myocytes (5) (6) (7) (8) . The slowed mechanical relaxation of HS myocytes was corrected by ␣-and ␤-Parv, with ␤-Parv showing evidence of a more potent effect (Fig. 5) . The 25, 50, and 75% relaxation times in ␤-Parv HS myocytes were corrected, and even accelerated, relative to control. Furthermore, ␤-Parv significantly accelerated 50 and 75% relaxation times compared with ␣-Parv (Fig. 5, B and C) . In a subset of experiments, control myocytes were loaded with fura 2 for assessment of intracellular Ca 2ϩ transients. Consistent with the mechanical relaxation findings (Fig. 5) , ␤-Parv caused a faster decay in the Ca 2ϩ transient than ␣-Parv (see supplemental data).
We next examined the dose-response relationship for the Parv isoforms (Figs. 6 and 7) . The dose-response relationship is made possible by the high efficiency (ϳ100%) and synchronization of gene delivery in vitro. Thus it is possible to assess myocytes at specified time points after gene transfer as [Parv] increases in the myocytes. In recent dose-response studies, we showed that genetic titration of ␣-Parv produces an effective concentration range over which relaxation performance is enhanced while myocyte contractility is maintained (7). Specifically, at 48 h after gene transfer, [␣-Parv] was estimated to be ϳ0.015 mM and to increase to ϳ0.1 mM at 72 h. We therefore tested whether analysis of myocytes at 48 h after gene transfer, when Western blot data showed reduced expression of Parv compared with that at 72 h (Fig. 6A) , would demonstrate differential effects of Parv isoforms on the function of HS- treated myocytes. At 72 h, the estimated ␤-Parv expression was lower than ␣-Parv expression (ϳ0.03 vs. ϳ0.12 mM; Fig. 6B) . At 48 h, Parv expression was reduced in both groups, with ␤-Parv barely detectable above background (Fig. 6A) . At 48 h, the contractility of the HS cardiac myocytes was not significantly affected by either Parv isoform (Fig. 6E) . Both Parv isoforms significantly accelerated mechanical relaxation, with ␤-Parv having a more robust effect than ␣-Parv (P Ͻ 0.05; Fig.  7) . Specifically, times to 50 and 75% relaxation were significantly less in ␤-Parv than in ␣-Parv myocytes (P Ͻ 0.05; Fig.  7 ). These results provide evidence of a more potent dose response for ␤-Parv, with a more dramatic functional effect at reduced concentration, than for ␣-Parv.
DISCUSSION
Heart failure is a leading cause of combined morbidity and mortality in humans. It has been estimated that 40% of human heart failure results specifically from diastolic dysfunction with normal systolic performance (21) . The DS rat is a wellcharacterized genetic model of hypertension and cardiac hypertrophy that progresses to CHF owing to diastolic dysfunction with preserved systolic performance. We used this animal model of diastolic heart failure to investigate at the isolated adult cardiac myocyte level the comparative effects of naturally occurring isoforms of the delayed Ca 2ϩ buffer Parv. Results demonstrate, for the first time, greater acceleration of Fig. 7 . Time-dependent dose-response relationships for ␣-and ␤-Parv expression effect on sarcomere relaxation times (ms). All data were collected from myocytes of high-salt-treated animals assigned to groups as follows: no virus (control, untreated) at day 2 (n ϭ 90) and day 3 (n ϭ 68), ␣-Parv at day 2 (n ϭ 71) and day 3 (n ϭ 62), and ␤-Parv at day 2 (n ϭ 71) and day 3 (n ϭ 77). C-E: summary of time-dependent effects of Parv expression on baseline sarcomere length (C), peak sarcomere shortening length (D), and amplitude of the peak height (E). Treatments include no virus (high salt) at day 2 (n ϭ 90) and day 3 (n ϭ 68), ␣-Parv (high salt ϩ ␣-PV) at day 2 (n ϭ 71) and day 3 (n ϭ 62), and ␤-Parv (high salt ϩ ␤-PV) at day 2 (n ϭ 71) and day 3 (n ϭ 77). Values are means Ϯ SE. *P Ͻ 0.05 vs. high salt within the same day. †P Ͻ 0.05 vs. day 2 within the same group. relaxation and at a lower estimated concentration by ␤-Parv than by ␣-Parv. On the basis of our recent mathematical modeling studies of Parv and cardiac excitation-contraction coupling (7, 9), we hypothesize that this Parv isoform-dependent enhanced functional performance is due to the greater cation affinities of ␤-Parv than ␣-Parv.
Recent experimental and modeling studies by Coutu et al. (6 -9) We tested the hypothesis in the present study that a naturally occurring alternative Parv isoform demonstrated to have a primary structure different from that of ␣-Parv may, in fact, have a more favorable outcome in terms of myocyte mechanical performance. Theoretically, a given Parv isoform would be considered beneficial if it minimized systolic Ca 2ϩ buffering while still retaining some capacity for Ca 2ϩ buffering in the diastolic phase of the cardiac cycle. More specifically, in principle, a Parv isoform with increased Mg 2ϩ affinity relative to ␣-Parv is modeled to achieve delayed Ca 2ϩ binding during a cardiac twitch, thus potentially preserving contractility while speeding relaxation (7). ␤-Parv has an association constant for Mg 2ϩ of 2.83 ϫ 10 4 M Ϫ1 . Relative to ␣-Parv, therefore, ␤-Parv has an apparent 16% increase in Mg 2ϩ affinity. If this increase in Mg 2ϩ affinity is due to reduced off-rate, modeling studies suggest that it may be relevant, inasmuch as Mg 2ϩ must dissociate from Parv before binding Ca 2ϩ . ␤-Parv also has an apparent 218% increase in Ca 2ϩ affinity relative to ␣-Parv and would also be expected to affect buffering. Modeling studies in part support this analysis, in particular in showing sarcomere length amplitude effects (see supplemental Fig. 3 ). There are, however, limitations to this analysis. 1) The biochemically determined cation-binding constants for Parv isoforms have not been determined under identical experimental conditions.
2) It is unknown whether differences in divalent cation affinities or kinetics obtained in biochemical assays would translate to the same differences in the more complex intracellular milieu of the cardiac myocyte, that is, other mono/divalent ion content, pH, ionic strength, and temperature. 3) Affinity differences could be due to a change in association and/or dissociation kinetics, which we did not determine. These confounding issues notwithstanding, the experimental results in cardiac myocytes presented here provide new mechanical evidence that ␤-Parv demonstrates a more potent dose response than ␣-Parv by causing a greater acceleration of relaxation at lower relative [Parv] within the myocyte. Thus, although there are uncertainties regarding the precise binding characteristics of Parv isoforms, these physiological findings are evidence that even small amounts of ␤-Parv, barely detectable above background on Western blot analysis and likely Ͻ0.001 mM, may be more potent than 5-to 10-fold higher [␣-Parv] in terms of hastening relaxation rates of adult cardiac myocytes. The basis for this enhanced function is not known but could, for example, relate to altered association/dissociation rates. The functional results of the present study, which was purposefully conducted in the most straightforward setting of the isolated single myocyte, could have implications for genetic-or protein-based strategies to introduce Parv into the more complex setting of heart muscle in vivo in an attempt to speed myocardial relaxation performance (29) .
In summary, an animal model of CHF was demonstrated at the adult cardiac myocyte level to have slow relaxation and preserved contractility and was used here as a cellular model of isolated diastolic dysfunction. Comparative studies for Parv isoforms demonstrated effective correction of slow relaxation in this model. Genetic titration of [Parv] demonstrated conditions under which relaxation could be accelerated and contractility preserved. It is estimated that ␤-Parv is ϳ10 times more potent than ␣-Parv in terms of accelerating mechanical relaxation. This Parv isoform-dependent differential dose response may be useful in designing therapies directed at diastolic dysfunction in the failing heart. In future studies, it will be interesting and important to employ in vivo gene transfer technologies to determine whether the results obtained here in adult cardiac myocytes will effectively translate to the complexities of the diseased heart in small and large mammals in vivo.
